Fig. 6.

Mean ± SD CECD at baseline and during treatment in the phase 1/2 study. Study eyes received a single administration of bimatoprost implant 10 µg, and fellow eyes were treated with topical bimatoprost 0.03% QD. Eyes were censored from the analysis at the time of implant re-treatment but could have received topical rescue IOP-lowering medication and remained in the analysis. The differences between groups (study eye minus fellow eye) and 95% CIs of the differences were calculated using paired t tests. BL baseline, CECD central corneal endothelial cell density, CI confidence interval, IOP intraocular pressure, M month, QD once daily, SD standard deviation, W week